Studies Seek to Find Female Biologic Factors That Affect HIV

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 10
Volume 10
Issue 10

BETHESDA, Maryland-A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

BETHESDA, Maryland—A 5-year, $17.5-million program will investigate how HIV infection affects adolescent and adult women. Three research centers will house the Women’s HIV Pathogenesis Program, funded by the National Institute of Child Health and Human Development (NICHD). Researchers at the centers will collaborate with others in an effort to identify biologic factors unique to women that affect HIV.

The centers will be located at the University of Washington in Seattle, the Gladstone Institute of Virology in San Francisco, and Rush-Presbyterian-St. Luke’s Medical Center in Chicago.

Researchers will focus on various subpopulations, including minority women, lesbians, female substance abusers, and women approaching or experiencing menopause. Understanding biologic factors unique to women could provide insights into how they become infected with the virus and transmit it to others, how the disease progresses in women after infection takes place, and how the disease affects women differently from men, NICHD said.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
5 experts are featured in this series
2 experts are featured in this series.
5 experts are featured in this series
2 experts are featured in this series.
Taletrectinib showed improved efficacy in patients with ROS1-positive non–small cell lung cancer who were treatment-naïve.
“It’s a drug that I’m very comfortable with, and it is a drug I’ll likely use primarily in the first-line setting,” stated Jorge Nieva, MD, on taletrectinib in non–small cell lung cancer.
4 experts in this video
4 experts in this video
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
Related Content